Beyond Air, Inc. (XAIR)

Beyond Air, Inc.'s stock price experienced a significant decline of 84.97% between April 7, 2025, and April 2, 2026. In January 2026, the company secured approximately $5 million in gross proceeds through a private placement financing. Also in January 2026, there was social media discussion regarding a potential acquisition of Beyond Air's NeuroNOS subsidiary, which led to a stock surge, but the agreement was terminated in March 2026. In February 2026, Beyond Air reported a 105% year-over-year increase in revenue to $2.2 million. In April 2026, the company announced a national group purchasing agreement to expand commercial access for LungFit PH and received a Nasdaq warning regarding its stock price falling below the minimum bid price requirement.

Demand seasonality for Beyond Air's products varies depending on the therapeutic area. The LungFit PRO system is expected to extend over two seasons, implying a seasonal component for VCAP treatment. LungFit PH has shown increasing commercial demand, and conditions treated in neonates typically do not exhibit strong seasonality. Products related to Beyond Cancer and NeuroNOS are generally not subject to significant demand seasonality.

Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company focused on leveraging nitric oxide (NO) to address various medical conditions, operating within the Healthcare sector. The company develops nitric oxide generators and delivery systems, along with NO-based therapeutics, with its core technology being the LungFit platform. Its main commercial product is LungFit PH, an FDA-approved and CE Mark-certified system for treating term and near-term neonates with hypoxic respiratory failure associated with pulmonary hypertension. Beyond Air's pipeline includes other LungFit systems in clinical trials for severe lung infections and ultra-high concentration NO for solid tumors, as well as investigational therapies for neurological disorders.

Beyond Air, Inc. is headquartered in Garden City, New York, United States. The LungFit PH system has received commercial approval in the United States, European Union, Australia, Thailand, and New Zealand. As of March 2025, its international commercial footprint included 18 countries, with new distribution agreements covering France, Romania, Turkey, and Morocco. By January 2026, Beyond Air had further expanded its LungFit PH distribution to five new countries, including Germany and Brazil, increasing its international presence to 39 countries. In August 2025, new distribution agreements were signed in Japan, South Korea, Costa Rica, Guatemala, Panama, and El Salvador, bringing the total international coverage to 34 countries.

Beyond Air's brand reputation has seen both positive and challenging events in the past year. Positive feedback has been received for the LungFit PH system, and the expansion of its global distribution network has been met with positive market reactions. The recent national GPO agreement further reinforces positive commercial momentum. However, concerns have been raised regarding financial strain, and the Nasdaq compliance warning could negatively affect investor confidence. The termination of the NeuroNOS acquisition agreement could also be viewed as a setback.

Major institutional owners of Beyond Air, Inc. include Alyeska Investment Group, L.P., Balyasny Asset Management Llc, Geode Capital Management, Llc, Vanguard Group Inc, Jane Street Group, Llc, Wealth Effects Llc, BlackRock, Inc., XTX Topco Ltd, Baldwin Brothers Inc/ma, and Virtu Financial LLC.